Krystal’s mission is to develop and deliver genetic medicines to patients using redosable gene therapies for the treatment of severe, life‑threatening or rare diseases that have limited or no approved therapies.
![a laboratory vial containing a clear liquid, used for gene therapy research.](https://www.krystalbio.com/wp-content/uploads/2023/09/cta1.jpeg)
Product
Krystal’s first commercial product, VYJUVEK®, is the first and only redosable gene therapy for the treatment of dystrophic epidermolysis bullosa.
![A Microscope used to research new gene therapies](https://www.krystalbio.com/wp-content/uploads/2023/09/cta2.jpeg)
Pipeline
With an extensive and promising pipeline, Krystal is advancing an integrated pipeline of genetic therapies to correct the root cause of serious and rare diseases.
![Stock market information](https://www.krystalbio.com/wp-content/uploads/2023/10/IR-banner-e1536797567858.jpg)
Investors
Find out about Krystal’s latest announcements, event information, Scientific Publications and our current corporate presentation.
Join the Team
Explore the exceptional career opportunities at Krystal where we are united by a shared purpose and driven to make a difference.
![Pittsburgh skyline behind the Pittsburgh bridge](https://www.krystalbio.com/wp-content/uploads/2023/09/pitt-bridge.png)
Discovering, developing, and commercializing genetic medicines with purpose